New progress in the development of new coronavirus vaccine in China

Read Time:1 Minute, 42 Second

The reporter recently learned from the State Council Joint Prevention and Control Mechanism Scientific Research and Tackling Group and related scientific research teams that China has made new progress in the development of new new coronavirus vaccines by adhering to multiple technical routes in parallel.

It is understood that there are three monovalent inactivated vaccines of variant strains of Omicron in China, Hong Kong and the United Arab Emirates are conducting sequential clinical trials, and the trials are progressing smoothly. Nine multivalent vaccines involving variant strains have entered clinical trials, some of which are in phase III clinical trials. Meanwhile, China is actively deploying to advance the development of broad-spectrum vaccines.

Recently, another adenovirus vector vaccine for inhalation and a recombinant protein vaccine have been approved for emergency use in a defined population for sequential booster immunization six months after completion of two doses of inactivated vaccine.

The recombinant novel coronavirus vaccine for inhalation (adenovirus vector type 5) is administered by oral inhalation at approximately one-fifth the dose administered by intramuscular injection. The recombinant novel coronavirus fusion protein vaccine has been tested in phase III clinical trials. Analysis of key data from the phase III clinical trials showed that the recombinant protein vaccine, when used for sequential booster immunization on top of two doses of inactivated vaccine, provides good protection against neoconiosis (mild and above) caused by infection with Omicron variant strains and has a good safety profile.

Experts from the Task Force Working Group on Vaccine Research and Development of the Joint Prevention and Control Mechanism of the State Council said that in the face of the complex epidemic situation, vaccination remains an effective measure for active immunization.

At present, 46 new coronavirus vaccines have entered clinical trials in China, 21 have been approved for phase III clinical trials outside China, 9 vaccines such as inactivated vaccines, adenovirus vector vaccines and recombinant protein vaccines have been approved for conditional listing or emergency use, and 3 vaccines have been included in the WHO emergency use list.